Diane Hershock, MD
Hematology & Oncology · Hershey, PANPI 1770652158
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,500 of the $5,364 with a category attached, or 83.9%. Amgen accounts for 83.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $4,670 and has fallen 97.9% since, to $100 in 2025.
Across 19 payments — averaging $282.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- AstraZeneca$200
- Gilead$134
- E.r. Squibb & Sons, L.L.C.$129
- Seagen Inc.$100
- Incyte Corporation$99
- plus $202 from 4 others
Across 6 payments — averaging $983.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Array Biopharma Inc$4K
- Amgen$2K
What the payments were for
- Consulting fees$4,50084%
- Food & beverage$3396%
- Education$52510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $4,500 |
| AstraZeneca | 2 | $200 |
| Gilead | 3 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $129 |
| Seagen Inc. | 1 | $100 |
| Incyte Corporation | 2 | $99 |
| Astellas Pharma US Inc | 2 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $70 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Novartis | 1 | $13 |
How this compares
$5,364 in reported general payments places this provider in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 19 | $268,642 |
| RevlimidLenalidomide | 12 | $220,069 |
| EliquisApixaban | 49 | $35,893 |
| Anastrozole | 87 | $3,129 |
| Prochlorperazine Maleate | 64 | $566 |
| Ondansetron Hcl | 81 | $513 |
| Dexamethasone | 23 | $502 |
| Letrozole | 18 | $482 |
| Nystatin | 19 | $426 |
| Fluconazole | 17 | $380 |
| Levothyroxine Sodium | 32 | $335 |
| Prednisone | 53 | $251 |
| Pantoprazole Sodium | 30 | $243 |
| Hydroxyurea | 11 | $235 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $224 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hershey
- Kevin RakszawskiHershey$237K
- Chandra BelaniHershey$149K
- Jeffrey PuHershey$103K
- Cristina TruicaHershey$102K
- David NguyenHershey$81K
- Joseph DrabickHershey$53K
- Patrick MaHershey$42K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.